April 13, 2026
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, explore how prior exposure to chemotherapy influences second-line treatment decisions. They emphasize the importance of repeat biopsy, both tissue and liquid, to identify resistance mechanisms, including small cell transformation. The discussion also highlights how clinicians balance molecular findings with clinical tempo when selecting subsequent therapies.
Related Posts
The Emerging Role of ADCs in EGFR-Mutant NSCLC
Future Directions: Toward Personalized EGFR Therapy in NSCLC
The Evolution of Frontline Therapy in EGFR-Mutant NSCLC
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Rethinking High-Risk EGFR-Mutant NSCLC
